These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 28603408)
1. Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies. Singh RP; Staurenghi G; Pollack A; Adewale A; Walker TM; Sager D; Lehmann R Clin Ophthalmol; 2017; 11():1021-1029. PubMed ID: 28603408 [TBL] [Abstract][Full Text] [Related]
2. Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies. Singh RP; Lehmann R; Martel J; Jong K; Pollack A; Tsorbatzoglou A; Staurenghi G; Cervantes-Coste Cervantes G; Alpern L; Modi S; Svoboda L; Adewale A; Jaffe GJ Ophthalmology; 2017 Jun; 124(6):776-785. PubMed ID: 28268098 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Singh R; Alpern L; Jaffe GJ; Lehmann RP; Lim J; Reiser HJ; Sall K; Walters T; Sager D Clin Ophthalmol; 2012; 6():1259-69. PubMed ID: 22927737 [TBL] [Abstract][Full Text] [Related]
4. Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy. Pollack A; Staurenghi G; Sager D; Mukesh B; Reiser H; Singh RP Br J Ophthalmol; 2017 Apr; 101(4):423-427. PubMed ID: 27388251 [TBL] [Abstract][Full Text] [Related]
5. Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site. Cable M Clin Ophthalmol; 2012; 6():997-1004. PubMed ID: 22815642 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification. Toyos MM Ophthalmol Ther; 2019 Jun; 8(2):261-270. PubMed ID: 30868419 [TBL] [Abstract][Full Text] [Related]
7. Prevention of Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery: The PROMISE Trial. Song W; Conti TF; Gans R; Conti FF; Silva FQ; Saroj N; Singh RP Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):170-178. PubMed ID: 32211907 [TBL] [Abstract][Full Text] [Related]
8. Prophylaxis of macular edema after cataract surgery in diabetic patients, topical Nepafenac versus intravitreal Ranibizumab. Howaidy A; Eldaly ZH; Anis M; Othman TM Eur J Ophthalmol; 2022 Jan; 32(1):205-212. PubMed ID: 33726537 [TBL] [Abstract][Full Text] [Related]
9. Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery. Lim BX; Lim CH; Lim DK; Evans JR; Bunce C; Wormald R Cochrane Database Syst Rev; 2016 Nov; 11(11):CD006683. PubMed ID: 27801522 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the Efficacy of Dexamethasone, Nepafenac, and Bromfenac for Preventing Pseudophakic Cystoid Macular Edema: an Open-label, Prospective, Randomized Controlled Trial. Campa C; Salsini G; Perri P Curr Eye Res; 2018 Mar; 43(3):362-367. PubMed ID: 29120255 [TBL] [Abstract][Full Text] [Related]
12. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. Lane SS; Modi SS; Lehmann RP; Holland EJ J Cataract Refract Surg; 2007 Jan; 33(1):53-8. PubMed ID: 17189793 [TBL] [Abstract][Full Text] [Related]
13. Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis. Ciulla TA; Kapik B; Grewal DS; Ip MS Ophthalmol Retina; 2021 Jul; 5(7):633-647. PubMed ID: 33130256 [TBL] [Abstract][Full Text] [Related]
14. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. ; Baker CW; Almukhtar T; Bressler NM; Glassman AR; Grover S; Kim SJ; Murtha TJ; Rauser ME; Stockdale C JAMA Ophthalmol; 2013 Jul; 131(7):870-9. PubMed ID: 23599174 [TBL] [Abstract][Full Text] [Related]
15. Impact of topical nonsteroidal anti-inflammatory drugs in prevention of macular edema following cataract surgery in diabetic patients. Alnagdy AA; Abouelkheir HY; El-Khouly SE; Tarshouby SM Int J Ophthalmol; 2018; 11(4):616-622. PubMed ID: 29675380 [TBL] [Abstract][Full Text] [Related]
16. Effect of Topical Nepafenac on Central Foveal Thickness following Panretinal Photocoagulation in Diabetic Patients. Abu Hussein NB; Mohalhal AA; Ghalwash DA; Abdel-Kader AA J Ophthalmol; 2017; 2017():3765253. PubMed ID: 28740734 [TBL] [Abstract][Full Text] [Related]
17. Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Mathys KC; Cohen KL Eye (Lond); 2010 Jan; 24(1):90-6. PubMed ID: 19229275 [TBL] [Abstract][Full Text] [Related]
18. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery. Maxwell WA; Reiser HJ; Stewart RH; Cavanagh HD; Walters TR; Sager DP; Meuse PA J Ocul Pharmacol Ther; 2008 Dec; 24(6):593-9. PubMed ID: 19040348 [TBL] [Abstract][Full Text] [Related]
19. Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double-masked, vehicle-controlled study. Stefansson E; Loftsson T; Larsen M; Papp A; Kaarniranta K; Munk MR; Dugel P; Tadayoni R; Acta Ophthalmol; 2023 Feb; 101(1):22-33. PubMed ID: 35848336 [TBL] [Abstract][Full Text] [Related]
20. Prospective, Randomized Study Comparing the Effect of 0.1% Nepafenac and 0.4% Ketorolac Tromethamine on Macular Thickness in Cataract Surgery Patients With Low Risk for Cystoid Macular Edema. Ramakrishnan S; Baskaran P; Talwar B; Venkatesh R Asia Pac J Ophthalmol (Phila); 2015; 4(4):216-20. PubMed ID: 26225780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]